Oklo Posts $0.22 Per-Share Loss and $1.86 Million in Third-Quarter Revenue
Key Facts
Oklo reported third-quarter results on November 6, 2026, for the period ended September 30, posting a loss of $0.22 per share, according to Investing.com. The loss was narrower than analysts’ estimate of $0.27 per share by $0.05, the report said. Revenue for the same period was $1.86 million, compared with consensus estimates of $1.01 million. The financial results put the company’s quarterly performance at the center of its update, while the company said management would hold a call to discuss the results on the day they were released. (f1, T01, T02, f2)
On revenue, actual results topped the third-quarter consensus estimate, with $1.86 million reported against $1.01 million, according to Investing.com. The per-share loss was $0.22, compared with an estimated loss of $0.27, which the report described as $0.05 better than estimated. Both figures relate to the period ended September 30, 2026, for which Oklo reported results on November 6. Comparing revenue and the loss with analysts’ estimates provides two separate measures of the quarter’s results. (f1, T01, T02)
OKLO shares closed at $19.20 on November 6, according to Investing.com data. The source said the stock was down 56.84% over the previous three months and 82.96% over the previous twelve months. Before the results announcement, the stock had closed at $19.2 on November 5, according to EL7 data. The previous closing price provides a reference level before the results were released, while the declines cover two periods ending on November 6. (T03, f4)
Oklo describes its business as developing power plants that run on fast fission, building a domestic supply chain for important isotopes and working on nuclear fuel recycling, according to its investor relations website. The Groves project is part of the company’s operating backdrop: on August 6, 2026, it announced that the reactor had achieved first criticality less than a year after the project began. The company also reported second-quarter results on August 7, saying that quarter ended June 30, 2026. These milestones preceded the third-quarter results announced on November 6 and place the business update in the sequence of the company’s announcements during the year. (f3, T05, T04, f1)
On isotopes, Oklo announced on October 13 that it would advance the Groves-2 Forge project, initially focusing on producing lutetium-177 for targeted cancer therapies. The company said the U.S. Department of Energy selected 12 developers to work on 13 projects under the Nuclear Energy Launch Pad initiative, which supports the project’s progress. Co-founder and Chief Executive Officer Jacob DeWitte said Groves-2 Forge would add capabilities for target material irradiation, isotope processing and preparation. The company linked the move to commercial-scale isotope production to obtaining the appropriate licenses from the U.S. Nuclear Regulatory Commission. (T06, T07, T08, T09)
The company had scheduled its third-quarter earnings call for November 6, 2026, at 8:30 a.m. Eastern Time, with co-founder and Chief Executive Officer Jacob DeWitte and Chief Financial Officer Craig Bealmear participating, according to an investor relations announcement. The timing was set in the same announcement that reported the release of results for the quarter ended September 30. The call gives management an opportunity to provide a business update and discuss the period’s results, according to the company’s announcement. The call also falls on the same date the results were announced. (f1, f2)